CARISMA THERAPEUTICS
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strong cellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease. Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania.
CARISMA THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Life Science Medical Therapeutics
Founded:
2016-01-01
Address:
Philadelphia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.carismatx.com
Total Employee:
11+
Status:
Active
Contact:
484-899-0326
Email Addresses:
[email protected]
Total Funding:
121.85 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Apache Euro Google Maps US Privacy User Signal Mechanism Google Maps API AdBlock Acceptable Ads Google Maps Embed
Similar Organizations
Juno Therapeutics
Juno Therapeutics is a clinical-stage company, develops immunotherapies for the treatment of cancer.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
AbbVie Biotech Ventures
AbbVie Biotech Ventures investment in Series B - Carisma Therapeutics
IP Group
IP Group investment in Series B - Carisma Therapeutics
HealthCap
HealthCap investment in Series B - Carisma Therapeutics
Agent Capital
Agent Capital investment in Series B - Carisma Therapeutics
Wellington Partners
Wellington Partners investment in Series B - Carisma Therapeutics
Penn Medicine Co-Investment Program
Penn Medicine Co-Investment Program investment in Series B - Carisma Therapeutics
Livzon Pharmaceutical Group
Livzon Pharmaceutical Group investment in Series B - Carisma Therapeutics
4BIO Capital
4BIO Capital investment in Series B - Carisma Therapeutics
Solasta Ventures
Solasta Ventures investment in Series B - Carisma Therapeutics
SymBiosis LLC
SymBiosis LLC investment in Series B - Carisma Therapeutics
Key Employee Changes
Date | New article |
---|---|
2022-04-25 | Carisma Therapeutics Announces Appointment Of Michael Klichinsky, PharmD, PhD, As Chief Scientific Officer |
Official Site Inspections
http://www.carismatx.com Semrush global rank: 7.81 M Semrush visits lastest month: 437
- Host name: cloudproxy10062.sucuri.net
- IP address: 192.124.249.62
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago